The Hematologist

In this special podcast, Dr. Ken Anderson and Dr. Martin Tallman, program co-chairs for the Meeting on Hematologic Malignancies, talk about the exciting events that will be taking place at this year’s meeting, which will take place September 16 to 17 at the Fairmont Chicago in Millennium Park, Chicago, Illinois. Attendees will have the opportunity to hear world-class experts in hematologic malignancies discuss the latest developments in clinical care, and learn about their own treatment approaches based on available data. The content will be structured as “How I Treat” sessions on core malignancies, including leukemia, lymphoma, myelodysplastic syndromes, myeloma, and myeloproliferative neoplasms. Among the dynamic areas the two Chairs discuss in this podcast, targeted and immune therapies are some of the most highly anticipated this year in Chicago. Also taking center-stage are several new areas of interest including immune therapies in leukemias, unique toxicities such as cytokine release syndrome and in curative disease types, and numerous others. As Drs. Anderson and Tallman spotlight, all of these discussions will take place in the context of actual clinical cases. For more information about the meeting, visit www.hematology.org/malignancies, and to register go to www.hematology.org/malignancies/registration.aspx.

Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/

In his Diffusion article from the July/August issue of The Hematologist, Dr. Adam Cuker (University of Pennsylvania) covers options to reduce the incidence of heparin-induced thrombocytopenia (HIT), treating it as a preventable nosocomial disease rather than an unavoidable iatrogenic disorder. He looks at the study “Reducing the hospital burden of heparin-induced thrombocytopenia: impact of an avoid-heparin program,” which was led by Dr. William Geerts (Sunnybrook Health Sciences Center) who joins Dr. Cuker in this stimulating conversation. You can find Dr. Cuker’s Diffusion article online at www.hematology.org/Thehematologist/Diffusion/5646.aspx.

Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/

In her Diffusion article from the May/June issue of The Hematologist, Dr. Ann LaCasce (Dana-Farber Cancer Institute) discusses the use of the recently FDA-approved drug venetoclax for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Dr. Andrew Roberts (Walter + Eliza Hall Institute of Medical Research) shares his thoughts about the drug and his experience with the first phase 1 dose-escalation study of daily oral venetoclax in patients with relapsed or refractory CLL/SLL in this thought-provoking conversation. You can find Dr. LaCasce’s Diffusion article online at www.hematology.org/Thehematologist/Diffusion/5479.aspx.

Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/

In his Diffusion article from the March/April issue of The Hematologist, Dr. Michael DeBaun (Vanderbilt University School of Medicine) takes a look at the TWiTCH Trial, a multicenter, open-label, phase III, non-inferiority trial. Dr. Russell Ware (University of Cincinnati and Cincinnati Children's Hospital), the national Principal Investigator for this NIH-funded trial conducted under the sponsorship of an FDA IND, joins Dr. DeBaun in this conversation. You can find the diffusion online at www.hematology.org/Thehematologist/Diffusion/4943.aspx.

Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/

In her Diffusion article from the November/December issue of The Hematologist, Dr. Pamela Becker (Institute for Stem Cell and Regenerative Medicine and Center for Cancer Innovation, University of Washington, Seattle, WA) talks about the many mutations identified in acute myeloid leukemia (AML) and the efforts of investigators to find a practical application of this information in modifying treatment. Dr. Jeffry Klco (St. Jude Children’s Research Hospital, Memphis, TN) and Dr. Timothy Ley (McDonnell Genome Institute and Siteman Cancer Center, Washington University, St. Louis, MO), co-authors of the JAMA article join Dr. Becker in this discussion. You can find the diffusion online at www.hematology.org/Thehematologist/Diffusion/4487.aspx.

Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/

In his Diffusion article from the September/October issue of The Hematologist, Dr. Adam Cuker (Penn-CHOP Blood Center for Patient Care and Discovery, University of Pennsylvania, Philadelphia, PA) discusses the BRIDGE study, which was led by Dr. Thomas Ortel (Duke University Medical Center, Durham, NC). Dr. Cuker concludes that, while more data are needed, there may be high-risk patients or procedures for which bridging is appropriate, which were not originally covered in the study. In this podcast, Drs. Cuker and Ortel thoroughly discuss the design, outcomes, and limitations of the BRIDGE study and explore how its results may inform clinical practice and treatment of atrial fibrillation and other disorders. Read the article here: www.hematology.org/Thehematologist/Diffusion/4310.aspx

Music: "Jellyfish in Space" Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/

In his recent Diffusion article from the July/August issue of The Hematologist, Dr. David Garcia (University of Washington School of Medicine, University of Washington Medical Center, Seattle, WA) discusses the PREPIC2 study. The PREPIC2 results, published in JAMA, highlight the benefits of well-managed anticoagulation in patients with high-risk pulmonary embolism. In this podcast, Dr. Garcia sheds additional light on the study as well as its ramifications throughout the field. The Hematologist Editor-in-Chief, Dr. Jason Gotlib (Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA) leads the discussion. Read the article here: http://www.hematology.org/Thehematologist/Diffusion/4130.aspx

Music: "Jellyfish in Space" Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 http://creativecommons.org/licenses/by/3.0/

The strategic roadmap developed at the original ASH Meeting on Lymphoma Biology held in August 2014 was recently published in Blood. To continue this important conversation, Dr. Ann LaCasce (Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA) and Dr. David Weinstock (Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA) have contributed a companion article, just published in the May/June issue of The Hematologist. This podcast features additional insight from the authors, with The Hematologist Editor-in-Chief Dr. Jason Gotlib (Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA) moderating the discussion. Read the article here: http://www.hematology.org/Thehematologist/Features/4003.aspx

Music: "Jellyfish in Space" Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 http://creativecommons.org/licenses/by/3.0/